News | June 02, 2022
Vial to launch oncology CRO, Arati Rao named as First Advisor
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Subscribe To Our Newsletter & Stay Updated
